Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs.
about
Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia TherapyExtra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2).Assessment of drug transporter function using fluorescent cell imagingComputational modeling to accelerate the identification of substrates and inhibitors for transporters that affect drug dispositionThe synthesis and characterization of cellular membrane affinity chromatography columns for the study of human multidrug resistant proteins MRP1, MRP2 and human breast cancer resistant protein BCRP using membranes obtained from Spodoptera frugiperdaABCG2-dependent dye exclusion activity and clonal potential in epithelial cells continuously growing for 1 month from limbal explants.Exploring the cellular accumulation of metal complexes.Effluxing ABC transporters in human corneal epithelium.Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport.Transport in technicolor: mapping ATP-binding cassette transporters in sea urchin embryos.In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats.In silico structure-based screening of versatile P-glycoprotein inhibitors using polynomial empirical scoring functions.Characterization of a pituitary-tumor-derived cell line, TtT/GF, that expresses Hoechst efflux ABC transporter subfamily G2 and stem cell antigen 1.A high-content assay strategy for the identification and profiling of ABCG2 modulators in live cells.HZ08 reverse P-glycoprotein mediated multidrug resistance in vitro and in vivo.Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.Intestinal ciprofloxacin efflux: the role of breast cancer resistance protein (ABCG2).A substrate pharmacophore for the human organic cation/carnitine transporter identifies compounds associated with rhabdomyolysis.The Inhibitor Ko143 Is Not Specific for ABCG2BCRP Inhibition: from Data Collection to Ligand-Based Modeling.A structure-activity relationship study of ABCC2 inhibitors.Intracellular drug bioavailability: a new predictor of system dependent drug disposition.Organic cation transporter 1 (OCT1) is involved in pentamidine transport at the human and mouse blood-brain barrier (BBB).A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier.Advances in PET imaging of P-glycoprotein function at the blood-brain barrier.PXR/CYP3A4-humanized mice for studying drug-drug interactions involving intestinal P-glycoprotein.Computational analysis and predictive modeling of polymorph descriptors.Comparative Localization and Functional Activity of the Main Hepatobiliary Transporters in HepaRG Cells and Primary Human Hepatocytes.Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoatePET and SPECT radiotracers to assess function and expression of ABC transporters in vivoThe antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the blood-brain barrier: a positron emission tomography study.ABC transporter activity linked to radiation resistance and molecular subtype in pediatric medulloblastoma.Enhancement of 5-aminolevulinic acid-based fluorescence detection of side population-defined glioma stem cells by iron chelation.ABCG2 confers promotion in gastric cancer through modulating downstream CRKL in vitro combining with biostatistics mining.An experimental approach to evaluate the impact of impaired transport function on hepatobiliary drug disposition using Mrp2-deficient TR- rat sandwich-cultured hepatocytes in combination with Bcrp knockdown.Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption.Intestinal transporters for endogenic and pharmaceutical organic anions: the challenges of deriving in-vitro kinetic parameters for the prediction of clinically relevant drug-drug interactions.
P2860
Q26780502-0278E188-DA10-43B4-BCF5-DB869F192210Q28575931-DF1A8DAC-EE2F-401E-AD6D-72A463B317B9Q30234940-874E3DDD-A5A7-49DB-8381-3CCF75EB4FEFQ30364846-6AF59C26-26D9-48DC-995D-DCD984A7D95FQ30571452-03C2ED88-6907-4D77-B9A1-130B3CD7F3CEQ33599159-CBB00D3C-9115-42A9-9514-D1D0F1C11285Q33833252-FAC3A1D1-C1E9-4303-8D4E-D22AD2DB45D8Q33851021-69CDDA34-A581-49F9-B5EB-02FC096ECEBDQ33866011-043AF8D1-08DB-4F7A-8B1C-AA83145D33CAQ34003651-D82FB459-2A79-4CBF-8D60-DB11FFA798B3Q34065294-3E54261F-2F91-4F9D-86F4-DAC678EFFF24Q34124847-C97A26FA-9369-4146-92DE-1B37CCDBF47EQ34173709-063F096A-517D-482C-90F2-CE1F8A1685DCQ34211108-DFD9C3C0-D35B-4103-ACC7-022003166E3CQ34414201-DC4ECF61-258D-42DF-937A-1428F6E70E89Q34861698-335F1296-3AE4-4A08-9EAE-089BDD9FB0B0Q34977187-F49446F9-C3DF-4322-A5EB-B48299C668DBQ35091852-B3D90B3B-5CE5-4892-9C0C-A20F06535FAEQ35187902-92AE65ED-C036-47D1-974A-0B3AF61CB736Q35579522-3E6BD798-1797-404C-9EBC-A668839FFC35Q35869583-F053C600-6ED2-4590-A797-823D5E4BF2F7Q35962045-2618B35F-7A71-4317-A982-716FF3D1D8A0Q36093462-E48DD4F3-313B-48DB-B071-E489D74ADA77Q36276676-D34CA679-7584-440C-BC1D-6BE7D38864FCQ36287236-19ADD4F5-0168-4E13-AA73-537B99AC807CQ36329959-5E0555EF-EF63-4B2A-9611-C6A57DFA95F9Q36386154-47CBD4B2-6A1A-4AF0-8670-BE65EC52C554Q36638627-777F5429-993A-45B0-BBA7-07BF9603BE4CQ36675727-361FCFC7-FDD6-48C3-94C7-CBDCE37D4EBDQ36687860-6490B4A3-FF3C-4458-A08D-D136E53404E6Q36801745-B2B7B8ED-1151-4CEC-866B-46EFBA58DC1DQ36949864-AAB89B6A-E6AD-42E6-BCE3-795BB6CC866EQ36953090-8C3E6E9E-0267-4537-A174-C52CF1E9304FQ37185659-FD79F2F1-E834-43CD-A17D-3D46439D117FQ37365043-C7A99460-6CFE-46BC-9159-47B0F535EF06Q37627644-8CE6E38F-C21E-489D-81B9-41B30F667FBBQ37706336-4EE4BF4D-6DCA-4A51-B069-9D6B439D32F0Q37714185-44B03F5B-5A95-44D1-BEEB-C22B7280A153Q38038547-97E4149C-2002-4E03-AD99-6867D9E118D9Q38051447-7619E252-9F22-4F74-BD5E-81CF6467DFB4
P2860
Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Identification of novel specif ...... d MRP2 among registered drugs.
@en
Identification of novel specif ...... d MRP2 among registered drugs.
@nl
type
label
Identification of novel specif ...... d MRP2 among registered drugs.
@en
Identification of novel specif ...... d MRP2 among registered drugs.
@nl
prefLabel
Identification of novel specif ...... d MRP2 among registered drugs.
@en
Identification of novel specif ...... d MRP2 among registered drugs.
@nl
P50
P1476
Identification of novel specif ...... nd MRP2 among registered drugs
@en
P2093
Jenny M Pedersen
Per Artursson
P2860
P304
P356
10.1007/S11095-009-9896-0
P577
2009-05-07T00:00:00Z